RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
5.24
+3.97 (+0.19%)
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous Close5.23
Open5.25
Bid0.00 x 800
Ask0.00 x 1800
Day's Range4.97 - 5.44
52 Week Range4.71 - 23.28
Volume34,403
Avg. Volume32,025
Market Cap21.06M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Rexahn Announces Move to Nasdaq

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Capital Market from its current listing on NYSE American. “As home to many innovative and growth-oriented life science companies, Nasdaq is a natural fit for Rexahn,” said Douglas Swirsky, president and chief executive officer of Rexahn.

  • Rexahn Pharmaceuticals, Inc.'s (NYSEMKT:RNN) Profit Outlook
    Simply Wall St.2 months ago

    Rexahn Pharmaceuticals, Inc.'s (NYSEMKT:RNN) Profit Outlook

    Rexahn Pharmaceuticals, Inc.'s (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical...

  • GlobeNewswire2 months ago

    Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

    ROCKVILLE, Md., May 13, 2019 -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient.

  • Benzinga3 months ago

    China Licensing Deal Sends Nanocap Rexahn Pharma Rocketing Higher

    Rexahn Pharmaceuticals, Inc. (NYSE: RNN ) shares are advancing to a two-month high following an announcement from the company regarding a Chinese licensing deal.  Rexahn said it signed a collaboration ...

  • GlobeNewswire3 months ago

    Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage, biopharmaceutical company focused on oncology, and BioSense Global LLC, a New Jersey- and Suzhou, China-based biopharmaceutical company, today announced a collaboration and license agreement to advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China.

  • GlobeNewswire3 months ago

    Rexahn Effects 1-for-12 Reverse Stock Split

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that the Company’s previously announced 1-for-12 reverse stock split of outstanding shares of the Company’s common stock (the “Common Stock”) became effective today prior to the opening of trading on the NYSE American, and that the Common Stock will begin trading on a split-adjusted basis at the opening of trading today.

  • GlobeNewswire3 months ago

    Rexahn Announces Reverse Stock Split

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that its Board of Directors has approved a one-for-twelve (1-for-12) reverse stock split of its common stock that will become effective Friday, April 12, 2019, upon the filing of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of the State of Delaware. Beginning on April 12, 2019, Rexahn’s common stock will trade on NYSE American on a reverse split-adjusted basis under the new CUSIP number 761640309. As previously disclosed, at the Company’s Special Meeting of Stockholders held on March 26, 2019, Rexahn’s stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-five (1-for-5) and not more than one-for-fifteen (1-for-15).

  • GlobeNewswire4 months ago

    Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

    ROCKVILLE, M.D., March 27, 2019 -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve.

  • GlobeNewswire5 months ago

    Rexahn Pharmaceuticals Reports 2018 Financial Results

    ROCKVILLE, Md., March 08, 2019 -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve.

  • GlobeNewswire5 months ago

    Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients

    This multicenter, single-arm, open-label study is designed to evaluate the safety and efficacy of RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients. The primary endpoint is progression free survival and study is expected to be completed in the second half of 2019.

  • GlobeNewswire5 months ago

    Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors. Dr. Sullivan will chair a newly formed business development committee, which has been established to assist the board with its oversight of Rexahn’s business development activities with the goal of maximizing the value of the company’s current and future development programs.  Dr. Sullivan will also serve on the nominating and corporate governance committee.

  • GlobeNewswire5 months ago

    Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, presented updated preliminary safety and efficacy data from its ongoing Phase 2a clinical trial of RX-3117 in advanced urothelial (bladder) cancer at the 2019 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 15, 2019. The poster presentation reports updated interim data from the Phase 2a trial of RX-3117 monotherapy in advanced bladder cancer.

  • What You Must Know About Rexahn Pharmaceuticals, Inc.’s (NYSEMKT:RNN) Beta Value
    Simply Wall St.5 months ago

    What You Must Know About Rexahn Pharmaceuticals, Inc.’s (NYSEMKT:RNN) Beta Value

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) mightRead More...

  • GlobeNewswire6 months ago

    Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

    ROCKVILLE, Md., Feb. 06, 2019 -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve.

  • GlobeNewswire6 months ago

    Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. Douglas J. Swirsky, chief executive officer of Rexahn, stated, “This patent will significantly enhance the intellectual property portfolio covering RX-3117.

  • GlobeNewswire6 months ago

    Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    Rexahn Announces Pricing of Public Offering of Common Stock and Warrants

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced the pricing of an underwritten public offering of 10,750,000 shares of its common stock and warrants to purchase up to 10,750,000 shares of its common stock. Each share of common stock is being sold together in a fixed combination with a warrant to purchase one share of common stock at a combined offering price of $0.80 per share and related warrant. The gross proceeds of the offering to the Company are expected to be approximately $8.6 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants.

  • GlobeNewswire6 months ago

    Rexahn Announces Proposed Public Offering of Common Stock and Warrants

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Oppenheimer & Co. Inc. is acting as sole book-running manager for the offering.

  • GlobeNewswire6 months ago

    Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, presented updated, preliminary data from the ongoing Phase 2a clinical trial of RX-3117 in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) in first-line metastatic pancreatic cancer patients at the 2019 ASCO Gastrointestinal Cancers (ASCO GI) Symposium on January 18, 2019. The multicenter, single-arm, open-label study is designed to evaluate RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients.  The Phase 2a trial is expected to enroll 40 evaluable patients.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...

  • ACCESSWIRE6 months ago

    Biotech Breaking Out

    HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a ...

  • GlobeNewswire6 months ago

    Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will present updated preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with ABRAXANE® in first-line metastatic pancreatic cancer patients at the 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held January 17-19, 2019 at the Moscone West Building in San Francisco, CA. Title: A phase 1/2 study of RX-3117, an oral antimetabolite nucleoside, in combination with nab-paclitaxel (nab-pac) as first line treatment of metastatic pancreatic cancer (met-PC): Preliminary results.

  • Benzinga6 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...

  • GlobeNewswire7 months ago

    Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

    Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced an operational restructuring that will enable a more efficient development of its clinical-stage oncology pipeline. Rexahn is lowering its operating costs including eliminating six positions, reducing the company’s workforce to 10. “In order to maximize shareholder value, we are prioritizing our resource utilization, including by reducing overhead expenses and discretionary spending,” said Douglas Swirsky, president and chief executive officer of Rexahn.